Development of a local controlled release system for therapeutic proteins in the treatment of skeletal muscle injuries and diseases.
Animals
Muscle, Skeletal
/ metabolism
Mice
Polyethylene Glycols
/ chemistry
Delayed-Action Preparations
Microspheres
Fibrinogen
/ metabolism
Hydrogels
/ chemistry
Regeneration
/ drug effects
Myoblasts
/ metabolism
Humans
Cell Proliferation
/ drug effects
PAX7 Transcription Factor
/ metabolism
Male
Mice, Inbred C57BL
Muscular Diseases
/ drug therapy
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
02 Jul 2024
02 Jul 2024
Historique:
received:
12
07
2023
accepted:
04
04
2024
revised:
24
03
2024
medline:
3
7
2024
pubmed:
3
7
2024
entrez:
2
7
2024
Statut:
epublish
Résumé
The present study aims to develop and characterize a controlled-release delivery system for protein therapeutics in skeletal muscle regeneration following an acute injury. The therapeutic protein, a membrane-GPI anchored protein called Cripto, was immobilized in an injectable hydrogel delivery vehicle for local administration and sustained release. The hydrogel was made of poly(ethylene glycol)-fibrinogen (PEG-Fibrinogen, PF), in the form of injectable microspheres. The PF microspheres exhibited a spherical morphology with an average diameter of approximately 100 micrometers, and the Cripto protein was uniformly entrapped within them. The release rate of Cripto from the PF microspheres was controlled by tuning the crosslinking density of the hydrogel, which was varied by changing the concentration of poly(ethylene glycol) diacrylate (PEG-DA) crosslinker. In vitro experiments confirmed a sustained-release profile of Cripto from the PF microspheres for up to 27 days. The released Cripto was biologically active and promoted the in vitro proliferation of mouse myoblasts. The therapeutic effect of PF-mediated delivery of Cripto in vivo was tested in a cardiotoxin (CTX)-induced muscle injury model in mice. The Cripto caused an increase in the in vivo expression of the myogenic markers Pax7, the differentiation makers eMHC and Desmin, higher numbers of centro-nucleated myofibers and greater areas of regenerated muscle tissue. Collectively, these results establish the PF microspheres as a potential delivery system for the localized, sustained release of therapeutic proteins toward the accelerated repair of damaged muscle tissue following acute injuries.
Identifiants
pubmed: 38956034
doi: 10.1038/s41419-024-06645-2
pii: 10.1038/s41419-024-06645-2
doi:
Substances chimiques
Polyethylene Glycols
3WJQ0SDW1A
Delayed-Action Preparations
0
Fibrinogen
9001-32-5
Hydrogels
0
PAX7 Transcription Factor
0
Pax7 protein, mouse
0
poly(ethylene glycol)diacrylate
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
470Subventions
Organisme : Israel Science Foundation (ISF)
ID : 2130/19
Organisme : EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 Marie Skłodowska-Curie Actions (H2020 Excellent Science - Marie Skłodowska-Curie Actions)
ID : Renoir
Informations de copyright
© 2024. The Author(s).
Références
Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov. 2015;14:58–74.
pubmed: 25549588
doi: 10.1038/nrd4467
Qazi TH, Duda GN, Ort MJ, Perka C, Geissler S, Winkler T. Cell therapy to improve regeneration of skeletal muscle injuries. J Cachexia Sarcopeni. 2019;10:501–16.
doi: 10.1002/jcsm.12416
Frontera WR, Ochala J. Skeletal Muscle: A Brief Review of Structure and Function. Calcif Tissue Int. 2015;96:183–95.
pubmed: 25294644
doi: 10.1007/s00223-014-9915-y
Tedesco FS, Dellavalle A, Diaz-Manera J, Messina G, Cossu G. Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin Invest. 2010;120:11–9.
pubmed: 20051632
pmcid: 2798695
doi: 10.1172/JCI40373
Corona BT, Wenke JC, Ward CL. Pathophysiology of Volumetric Muscle Loss Injury. Cells Tissues Organs. 2015;202:180–8.
doi: 10.1159/000443925
Bonaldo P, Sandri M. Cellular and molecular mechanisms of muscle atrophy. Dis Model Mech. 2013;6:25–39.
pubmed: 23268536
pmcid: 3529336
doi: 10.1242/dmm.010389
Maffulli N, Del Buono A, Oliva F, Giai Via A, Frizziero A, Barazzuol M, et al. Muscle Injuries: A Brief Guide to Classification and Management. Transl Med UniSa. 2015;12:14–8.
pubmed: 26535183
Mackey AL, Mikkelsen UR, Magnusson SP, Kjaer M. Rehabilitation of muscle after injury - the role of anti-inflammatory drugs. Scand J Med Sci Spor. 2012;22:E8–E14.
doi: 10.1111/j.1600-0838.2012.01463.x
Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77–93.
pubmed: 19945913
doi: 10.1016/S1474-4422(09)70271-6
Leung DG, Wagner KR. Therapeutic Advances in Muscular Dystrophy. Ann Neurol. 2013;74:404–11.
pubmed: 23939629
pmcid: 3886293
doi: 10.1002/ana.23989
Shimizu-Motohashi Y, Miyatake S, Komaki H, Takeda S, Aoki Y. Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials. Am J Transl Res. 2016;8:2471–89.
pubmed: 27398133
pmcid: 4931144
Guiraud S, Chen HJ, Burns DT, Davies KE. Advances in genetic therapeutic strategies for Duchenne muscular dystrophy. Exp Physiol. 2015;100:1458–67.
pubmed: 26140505
doi: 10.1113/EP085308
Aggarwal SR. What’s fueling the biotech engine-2012 to 2013. Nat Biotechnol. 2014;32:32–9.
pubmed: 24406926
doi: 10.1038/nbt.2794
Dimitrov DS. Therapeutic proteins. Methods Mol Biol. 2012;899:1–26.
pubmed: 22735943
pmcid: 6988726
doi: 10.1007/978-1-61779-921-1_1
Rooney JE, Gurpur PB, Burkin DJ. Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy. P Natl Acad Sci USA. 2009;106:7991–6.
doi: 10.1073/pnas.0811599106
Van Ry PM, Wuebbles RD, Key M, Burkin DJ. Galectin-1 Protein Therapy Prevents Pathology and Improves Muscle Function in the mdx Mouse Model of Duchenne Muscular Dystrophy. Mol Ther. 2015;23:1285–97.
pubmed: 26050991
pmcid: 4817863
doi: 10.1038/mt.2015.105
Fairclough RJ, Wood MJ, Davies KE. Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet. 2013;14:373–8.
pubmed: 23609411
doi: 10.1038/nrg3460
Guiraud S, Roblin D, Kay DE. The potential of utrophin modulators for the treatment of Duchenne muscular dystrophy. Expert Opin Orphan D. 2018;6:179–92.
doi: 10.1080/21678707.2018.1438261
Rybalko VY, Pham CB, Hsieh PL, Hammers DW, Merscham-Banda M, Suggs LJ, et al. Controlled delivery of SDF-1 alpha and IGF-1: CXCR4(+) cell recruitment and functional skeletal muscle recovery. Biomater Sci-Uk. 2015;3:1475–86.
doi: 10.1039/C5BM00233H
Xu DQ, Zhao L, Li SJ, Huang XF, Li CJ, Sun LX, et al. Catalpol counteracts the pathology in a mouse model of Duchenne muscular dystrophy by inhibiting the TGF-beta1/TAK1 signaling pathway. Acta Pharm Sin. 2021;42:1080–9.
doi: 10.1038/s41401-020-00515-1
Estrellas KM, Chung L, Cheug LA, Sadtler K, Majumdar S, Mula J, et al. Biological scaffold-mediated delivery of myostatin inhibitor promotes a regenerative immune response in an animal model of Duchenne muscular dystrophy. J Biol Chem. 2018;293:15594–605.
pubmed: 30139748
pmcid: 6177591
doi: 10.1074/jbc.RA118.004417
Yaden BC, Croy JE, Wang Y, Wilson JM, Datta-Mannan A, Shetler P, et al. Follistatin: a novel therapeutic for the improvement of muscle regeneration. J Pharm Exp Ther. 2014;349:355–71.
doi: 10.1124/jpet.113.211169
Burks TN, Cohn RD. Role of TGF-beta signaling in inherited and acquired myopathies. Skelet Muscle. 2011;1:19.
Guardiola O, Lafuste P, Brunelli S, Iaconis S, Touvier T, Mourikis P, et al. Cripto regulates skeletal muscle regeneration and modulates satellite cell determination by antagonizing myostatin. Proc Natl Acad Sci USA. 2012;109:E3231–40.
pubmed: 23129614
pmcid: 3511144
doi: 10.1073/pnas.1204017109
Nielsen TL, Vissing J, Krag TO. Antimyostatin Treatment in Health and Disease: The Story of Great Expectations and Limited Success. Cells. 2021;10:533.
Amthor H, Hoogaars WM. Interference with myostatin/ActRIIB signaling as a therapeutic strategy for Duchenne muscular dystrophy. Curr Gene Ther. 2012;12:245–59.
pubmed: 22554312
doi: 10.2174/156652312800840577
Yan YT, Liu JJ, Luo Y, Chaosu E, Haltiwanger RS, Abate-Shen C, et al. Dual roles of Cripto as a ligand and coreceptor in the nodal signaling pathway. Mol Cell Biol. 2002;22:4439–49.
pubmed: 12052855
pmcid: 133918
doi: 10.1128/MCB.22.13.4439-4449.2002
Minchiotti G, Parisi S, Liguori GL, D’Andrea D, Persico MG. Role of the EGF-CFC gene cripto in cell differentiation and embryo development. Gene. 2002;287:33–7.
pubmed: 11992720
doi: 10.1016/S0378-1119(01)00892-7
Fiorenzano A, Pascale E, D’Aniello C, Acampora D, Bassalert C, Russo F, et al. Cripto is essential to capture mouse epiblast stem cell and human embryonic stem cell pluripotency. Nat Commun. 2016;7:12589.
Yun S, Yun CW, Lee JH, Kim S, Lee SH. Cripto Enhances Proliferation and Survival of Mesenchymal Stem Cells by Up-Regulating JAK2/STAT3 Pathway in a GRP78-Dependent Manner. Biomol Ther (Seoul). 2018;26:464–73.
pubmed: 28835002
doi: 10.4062/biomolther.2017.099
Strizzi L, Bianco C, Normanno N, Salomon D. Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis. Oncogene. 2005;24:5731–41.
pubmed: 16123806
doi: 10.1038/sj.onc.1208918
Shen MM, Schier AF. The EGF-CFC gene family in vertebrate development. Trends Genet. 2000;16:303–9.
pubmed: 10858660
doi: 10.1016/S0168-9525(00)02006-0
Lee SJ, Lehar A, Liu Y, Ly CH, Pham QM, Michaud M, et al. Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A. Proc Natl Acad Sci USA. 2020;117:30907–17.
pubmed: 33219121
pmcid: 7733802
doi: 10.1073/pnas.2019263117
Bianco C, Salomon DS. Targeting the embryonic gene Cripto-1 in cancer and beyond. Expert Opin Ther Pat. 2010;20:1739–49.
pubmed: 21073352
pmcid: 3059560
doi: 10.1517/13543776.2010.530659
Prezioso C, Iaconis S, Andolfi G, Zentilin L, Iavarone F, Guardiola O, et al. Conditional Cripto overexpression in satellite cells promotes myogenic commitment and enhances early regeneration. Front Cell Dev Biol. 2015;3:31.
Angrisano T, Varrone F, Ragozzino E, Fico A, Minchiotti G, Brancaccio M. Cripto Is Targeted by miR-1a-3p in a Mouse Model of Heart Development. International Journal of Molecular Sciences. 2023;24:12251.
Iavarone F, Guardiola O, Scagliola A, Andolfi G, Esposito F, Serrano A, et al. Cripto shapes macrophage plasticity and restricts EndMT in injured and diseased skeletal muscle. Embo Rep. 2020;21:e49075.
Guardiola O, Iavarone F, Nicoletti C, Ventre M, Rodriguez C, Pisapia L, et al. CRIPTO-based micro-heterogeneity of mouse muscle satellite cells enables adaptive response to regenerative microenvironment. Dev Cell. 2023;58:2896–913 e6.
pubmed: 38056454
doi: 10.1016/j.devcel.2023.11.009
Chirino AJ, Ary ML, Marshall SA. Minimizing the immunogenicity of protein therapeutics. Drug Discov Today. 2004;9:82–90.
pubmed: 15012932
doi: 10.1016/S1359-6446(03)02953-2
Vermonden T, Censi R, Hennink WE. Hydrogels for protein delivery. Chem Rev. 2012;112:2853–88.
pubmed: 22360637
doi: 10.1021/cr200157d
Censi R, Di Martino P, Vermonden T, Hennink WE. Hydrogels for protein delivery in tissue engineering. J Control Release. 2012;161:680–92.
pubmed: 22421425
doi: 10.1016/j.jconrel.2012.03.002
Lev R, Seliktar D Hydrogel biomaterials and their therapeutic potential for muscle injuries and muscular dystrophies. J R Soc Interface. 2018;15.
Seliktar D. Designing Cell-Compatible Hydrogels for Biomedical Applications. Science. 2012;336:1124–8.
pubmed: 22654050
doi: 10.1126/science.1214804
Yanev P, van Tilborg GAF, Boere KWM, Stowe AM, van der Toorn A, Viergever MA, et al. Thermosensitive Biodegradable Hydrogels for Local and Controlled Cerebral Delivery of Proteins: MRI-Based Monitoring of In Vitro and In Vivo Protein Release. ACS Biomater Sci Eng. 2023;9:760–72.
pubmed: 36681938
pmcid: 9930091
doi: 10.1021/acsbiomaterials.2c01224
Censi R, Vermonden T, van Steenbergen MJ, Deschout H, Braeckmans K, De Smedt SC, et al. Photopolymerized thermosensitive hydrogels for tailorable diffusion-controlled protein delivery. J Control Release. 2009;140:230–6.
pubmed: 19527757
doi: 10.1016/j.jconrel.2009.06.003
Hiemstra C, Zhong Z, Van Tomme SR, van Steenbergen MJ, Jacobs JJ, Otter WD, et al. In vitro and in vivo protein delivery from in situ forming poly(ethylene glycol)-poly(lactide) hydrogels. J Control Release. 2007;119:320–7.
pubmed: 17475360
doi: 10.1016/j.jconrel.2007.03.014
Solaro R, Chiellini F, Battisti A. Targeted Delivery of Protein Drugs by Nanocarriers. Materials. 2010;3:1928–80.
pmcid: 5445892
doi: 10.3390/ma3031928
Lev R, Bar-Am O, Lati Y, Guardiola O, Minchiotti G, Seliktar D Biomanufacturing Recombinantly Expressed Cripto-1 Protein in Anchorage-Dependent Mammalian Cells Growing in Suspension Bioreactors within a Three-Dimensional Hydrogel Microcarrier. Gels-Basel. 2023;9.
Almany L, Seliktar D. Biosynthetic hydrogel scaffolds made from fibrinogen and polyethylene glycol for 3D cell cultures. Biomaterials. 2005;26:2467–77.
pubmed: 15585249
doi: 10.1016/j.biomaterials.2004.06.047
Ben-David D, Srouji S, Shapira-Schweitzer K, Kossover O, Ivanir E, Kuhn G, et al. Low dose BMP-2 treatment for bone repair using a PEGylated fibrinogen hydrogel matrix. Biomaterials. 2013;34:2902–10.
pubmed: 23375953
doi: 10.1016/j.biomaterials.2013.01.035
Berdichevski A, Yameen HS, Dafni H, Neeman M, Seliktar D. Using bimodal MRI/fluorescence imaging to identify host angiogenic response to implants. P Natl Acad Sci USA. 2015;112:5147–52.
doi: 10.1073/pnas.1502232112
Cohen T, Kossover O, Peled E, Bick T, Hasanov L, Chun TT, et al. A combined cell and growth factor delivery for the repair of a critical size tibia defect using biodegradable hydrogel implants. J Tissue Eng Regen M. 2022;16:380–95.
doi: 10.1002/term.3285
Kossover O, Cohen N, Lewis JA, Berkovitch Y, Peled E, Seliktar D. Growth Factor Delivery for the Repair of a Critical Size Tibia Defect Using an Acellular, Biodegradable Polyethylene Glycol-Albumin Hydrogel Implant. Acs Biomater Sci Eng. 2020;6:100–11.
pubmed: 33463206
doi: 10.1021/acsbiomaterials.9b00672
Cohen SA, Simaan-Yameen H, Fuoco C, Gargioli C, Seliktar D Injectable hydrogel microspheres for sustained gene delivery of antisense oligonucleotides to restore the expression of dystrophin protein in duchenne muscular dystrophy. Eur Polym J. 2022;166.
Gonen-Wadmany M, Goldshmid R, Seliktar D. Biological and mechanical implications of PEGylating proteins into hydrogel biomaterials. Biomaterials. 2011;32:6025–33.
pubmed: 21669457
doi: 10.1016/j.biomaterials.2011.04.055
Schreiner MM, Raudner M, Szomolanyi P, Ohel K, Ben-Zur L, Juras V, et al. Chondral and Osteochondral Femoral Cartilage Lesions Treated with GelrinC: Significant Improvement of Radiological Outcome Over Time and Zonal Variation of the Repair Tissue Based on T Mapping at 24 Months. Cartilage. 2021;13:604s–16s.
pubmed: 32493044
doi: 10.1177/1947603520926702
Trattnig S, Ohel K, Mlynarik V, Juras V, Zbyn S, Korner A. Morphological and compositional monitoring of a new cell-free cartilage repair hydrogel technology - GelrinC by MR using semi-quantitative MOCART scoring and quantitative T2 index and new zonal T2 index calculation. Osteoarthr Cartil. 2015;23:2224–32.
doi: 10.1016/j.joca.2015.07.007
Ravi S, Peh KK, Darwis Y, Murthy BK, Singh TRR, Mallikarjun C. Development and Characterization of Polymeric Microspheres for Controlled Release Protein Loaded Drug Delivery System. Indian J Pharm Sci. 2008;70:303–9.
pubmed: 20046737
pmcid: 2792511
doi: 10.4103/0250-474X.42978
Pradhan S, Clary JM, Seliktar D, Lipke EA. A three-dimensional spheroidal cancer model based on PEG-fibrinogen hydrogel microspheres. Biomaterials. 2017;115:141–54.
pubmed: 27889665
doi: 10.1016/j.biomaterials.2016.10.052
Dikovsky D, Bianco-Peled H, Seliktar D. The effect of structural alterations of PEG-fibrinogen hydrogel scaffolds on 3-D cellular morphology and cellular migration. Biomaterials. 2006;27:1496–506.
pubmed: 16243393
doi: 10.1016/j.biomaterials.2005.09.038
Simaan-Yameen H, Bar-Am O, Saar G, Seliktar D. Methacrylated fibrinogen hydrogels for 3D cell culture and delivery. Acta Biomater. 2023;164:94–110.
Minchiotti G, Parisi S, Liguori G, Signore M, Lania G, Adamson ED, et al. Membrane-anchorage of Cripto protein by glycosylphosphatidylinositol and its distribution during early mouse development. Mech Dev. 2000;90:133–42.
pubmed: 10640699
doi: 10.1016/S0925-4773(99)00235-X
Franco CL, Price J, West JL. Development and optimization of a dual-photoinitiator, emulsion-based technique for rapid generation of cell-laden hydrogel microspheres. Acta Biomaterialia. 2011;7:3267–76.
pubmed: 21704198
doi: 10.1016/j.actbio.2011.06.011
Dikovsky D, Bianco-Peled H, Seliktar D. Defining the role of matrix compliance and proteolysis in three-dimensional cell spreading and remodeling. Biophys J. 2008;94:2914–25.
pubmed: 18178662
pmcid: 2267114
doi: 10.1529/biophysj.107.105841
Mironi-Harpaz I, Hazanov L, Engel G, Yelin D, Seliktar D. In-situ architectures designed in 3D cell-laden hydrogels using microscopic laser photolithography. Adv Mater. 2015;27:1933–8.
pubmed: 25655567
doi: 10.1002/adma.201404185
Cohen SA, Bar-Am O, Fuoco C, Saar G, Gargioli C, Seliktar D. In vivo restoration of dystrophin expression in mdx mice using intra-muscular and intra-arterial injections of hydrogel microsphere carriers of exon skipping antisense oligonucleotides. Cell Death Dis. 2022;13:779.
pubmed: 36085138
pmcid: 9463190
doi: 10.1038/s41419-022-05166-0
Berdichevski A, Shachaf Y, Wechsler R, Seliktar D. Protein composition alters in vivo resorption of PEG-based hydrogels as monitored by contrast-enhanced MRI. Biomaterials. 2015;42:1–10.
pubmed: 25542788
doi: 10.1016/j.biomaterials.2014.11.015
Riederer I, Negroni E, Bencze M, Wolff A, Aamiri A, Di Santo JP, et al. Slowing Down Differentiation of Engrafted Human Myoblasts Into Immunodeficient Mice Correlates With Increased Proliferation and Migration. Mol Ther. 2012;20:146–54.
pubmed: 21934656
doi: 10.1038/mt.2011.193
Birman T, Seliktar D. Injectability of Biosynthetic Hydrogels: Consideration for Minimally Invasive Surgical Procedures and 3D Bioprinting. Adv Funct Mater. 2021;31:2100628.
Cohen N, Toister E, Lati Y, Girshengorn M, Levin L, Silberstein L, et al. Cell encapsulation utilizing PEG-fibrinogen hydrogel supports viability and enhances productivity under stress conditions. Cytotechnology. 2018;70:1075–83.
pubmed: 29468479
pmcid: 6021291
doi: 10.1007/s10616-018-0204-x
Cohen N, Vagima Y, Mouhadeb O, Toister E, Gutman H, Lazar S, et al. PEG-fibrinogen hydrogel microspheres as a scaffold for therapeutic delivery of immune cells. Front Bioeng Biotechnol. 2022;10:905557.
pubmed: 36017344
pmcid: 9395737
doi: 10.3389/fbioe.2022.905557
Skuk D, Goulet M, Roy B, Piette V, Cote CH, Chapdelaine P, et al. First test of a “high-density injection” protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up. Neuromuscul Disord. 2007;17:38–46.
pubmed: 17142039
doi: 10.1016/j.nmd.2006.10.003
Hamami R, Simaan-Yameen H, Gargioli C, Seliktar D. Comparison of Four Different Preparation Methods for Making Injectable Microgels for Tissue Engineering and Cell Therapy. Regen Eng Transl Med. 2022;8:615–29.
doi: 10.1007/s40883-022-00261-2
Feng Q, Li DG, Li QT, Cao XD, Dong H. Microgel assembly: Fabrication, characteristics and application in tissue engineering and regenerative medicine. Bioact Mater. 2022;9:105–19.
pubmed: 34820559
Sivashanmugam A, Kumar RA, Priya MV, Nair SV, Jayakumar R. An overview of injectable polymeric hydrogels for tissue engineering. Eur Polym J. 2015;72:543–65.
doi: 10.1016/j.eurpolymj.2015.05.014
Panyam, Dali MA J, Sahoo SK, Ma WX, Chakravarthi SS, Amidon GL, et al. Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. J Control Release. 2003;92:173–87.
pubmed: 14499195
doi: 10.1016/S0168-3659(03)00328-6
Sah HK, Toddywala R, Chien YW. The Influence of Biodegradable Microcapsule Formulations on the Controlled-Release of a Protein. J Control Release. 1994;30:201–11.
doi: 10.1016/0168-3659(94)90026-4
Igartua M, Hernandez RM, Esquisabel A, Gascon AR, Calvo MB, Pedraz JL. Influence of formulation variables on the in-vitro release of albumin from biodegradable microparticulate systems. J Microencapsul. 1997;14:349–56.
pubmed: 9147284
doi: 10.3109/02652049709051138
Oss-Ronen L, Seliktar D. Polymer-conjugated albumin and fibrinogen composite hydrogels as cell scaffolds designed for affinity-based drug delivery. Acta Biomaterialia. 2011;7:163–70.
pubmed: 20643230
doi: 10.1016/j.actbio.2010.07.017
Kopac T, Abrami M, Grassi M, Rucigaj A, Krajnc M. Polysaccharide-based hydrogels crosslink density equation: A rheological and LF-NMR study of polymer-polymer interactions. Carbohyd Polym. 2022;277:118895.
Yom-Tov O, Neufeld L, Seliktar D, Bianco-Peled H. A novel design of injectable porous hydrogels with in situ pore formation. Acta Biomater. 2014;10:4236–46.
pubmed: 25034645
doi: 10.1016/j.actbio.2014.07.006
Rufaihah AJ, Vaibavi SR, Plotkin M, Shen J, Nithya V, Wang J, et al. Enhanced infarct stabilization and neovascularization mediated by VEGF-loaded PEGylated fibrinogen hydrogel in a rodent myocardial infarction model. Biomaterials. 2013;34:8195–202.
pubmed: 23891519
doi: 10.1016/j.biomaterials.2013.07.031
van de Wetering P, Metters AT, Schoenmakers RG, Hubbell JA. Poly(ethylene glycol) hydrogels formed by conjugate addition with controllable swelling, degradation, and release of pharmaceutically active proteins. J Control Release. 2005;102:619–27.
pubmed: 15681084
doi: 10.1016/j.jconrel.2004.10.029
Cruise GM, Scharp DS, Hubbell JA. Characterization of permeability and network structure of interfacially photopolymerized poly(ethylene glycol) diacrylate hydrogels. Biomaterials. 1998;19:1287–94.
pubmed: 9720892
doi: 10.1016/S0142-9612(98)00025-8
Peppas NA, Khare AR. Preparation, Structure and Diffusional Behavior of Hydrogels in Controlled-Release. Adv Drug Deliv Rev. 1993;11:1–35.
doi: 10.1016/0169-409X(93)90025-Y
Li JY, Mooney DJ. Designing hydrogels for controlled drug delivery. Nat Rev Mater. 2016;1:16071.
Dikovsky D, Bianco-Peled H, Seliktar D. Proteolytically Degradable Photo-Polymerized Hydrogels Made From PEG-Fibrinogen Adducts. Adv Eng Mater. 2010;12:B200–B9.
doi: 10.1002/adem.200980054
Peled E, Boss J, Bejar J, Zinman C, Seliktar D. A novel poly(ethylene glycol)-fibrinogen hydrogel for tibial segmental defect repair in a rat model. J Biomed Mater Res A. 2007;80:874–84.
pubmed: 17072852
doi: 10.1002/jbm.a.30928
Wang HX, Lau SY, Huang SJ, Kwan CY, Wong TM. Cobra venom cardiotoxin induces perturbations of cytosolic calcium homeostasis and hypercontracture in adult rat ventricular myocytes. J Mol Cell Cardiol. 1997;29:2759–70.
pubmed: 9344770
doi: 10.1006/jmcc.1997.0511
Ownby CL, Fletcher JE, Colberg TR. Cardiotoxin 1 from cobra (Naja naja atra) venom causes necrosis of skeletal muscle in vivo. Toxicon. 1993;31:697–709.
pubmed: 8342169
doi: 10.1016/0041-0101(93)90376-T
Chen XM, Astary GW, Sepulveda H, Mareci TH, Sarntinoranont M. Quantitative assessment of macromolecular concentration during direct infusion into an agarose hydrogel phantom using contrast-enhanced MRI. Magn Reson Imaging. 2008;26:1433–41.
pubmed: 18583082
pmcid: 3140426
doi: 10.1016/j.mri.2008.04.011
Krauze MT, Forsayeth J, Park JW, Bankiewicz KS. Real-time imaging and quantification of brain delivery of liposomes. Pharm Res. 2006;23:2493–504.
pubmed: 16972184
doi: 10.1007/s11095-006-9103-5
Hawke TJ, Garry DJ. Myogenic satellite cells: physiology to molecular biology. J Appl Physiol (1985). 2001;91:534–51.
pubmed: 11457764
doi: 10.1152/jappl.2001.91.2.534
Warhol MJ, Siegel AJ, Evans WJ, Silverman LM. Skeletal muscle injury and repair in marathon runners after competition. Am J Pathol. 1985;118:331–9.
pubmed: 3970143
pmcid: 1887882
Whalen RG, Harris JB, Butlerbrowne GS, Sesodia S. Expression of Myosin Isoforms during Notexin-Induced Regeneration of Rat Soleus Muscles. Dev Biol. 1990;141:24–40.
pubmed: 2391004
doi: 10.1016/0012-1606(90)90099-5
Yoshimoto Y, Ikemoto-Uezumi M, Hitachi K, Fukada S, Uezumi A. Methods for Accurate Assessment of Myofiber Maturity During Skeletal Muscle Regeneration. Front Cell Dev Biol. 2020;8:267.
Olguin HC, Pisconti A. Marking the tempo for myogenesis: Pax7 and the regulation of muscle stem cell fate decisions. J Cell Mol Med. 2012;16:1013–25.
pubmed: 21615681
pmcid: 4365881
doi: 10.1111/j.1582-4934.2011.01348.x
Yin H, Price F, Rudnicki MA. Satellite Cells and the Muscle Stem Cell Niche. Physiol Rev. 2013;93:23–67.
pubmed: 23303905
pmcid: 4073943
doi: 10.1152/physrev.00043.2011
Soglia F, Bordini M, Mazzoni M, Zappaterra M, Di Nunzio M, Clavenzani P, et al. The evolution of vimentin and desmin in Pectoralis major muscles of broiler chickens supports their essential role in muscle regeneration. Front Physiol. 2022;13:13380.
Wang Y, Lu J, Liu Y. Skeletal Muscle Regeneration in Cardiotoxin-Induced Muscle Injury Models. Int J Mol Sci. 2022;23:13380.
Sicari BM, Agrawal V, Siu BF, Medberry CJ, Dearth CL, Turner NJ, et al. A murine model of volumetric muscle loss and a regenerative medicine approach for tissue replacement. Tissue Eng Part A. 2012;18:1941–8.
pubmed: 22906411
pmcid: 3463275
doi: 10.1089/ten.tea.2012.0475